Enzolytics Inc. (ENZC) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Plano, TX, アメリカ. 現CEOは Steven Sharabura.
ENZC を有する IPO日 2009-04-08, 1 名の正社員, に上場 Other OTC, 時価総額 $1.18M.
Enzolytics, Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, it has created a proprietary cell line that produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics Inc. is based in Plano, Texas.
